Thursday, April 06, 2023 11:17:30 AM
Re KZR. I posted why I was reducing my position back in Jan . This famous quote comes to mind
Regarding ARDX and my diarrhea concern . Wife ( who has dialysis patients on phosphorous binders already ) states that most of her patients complain of constipation so it may not be a problem.
She plans on introducing them slowly to the new drug with the existing phosphorous binders they are already on .....and then try and reduce the number of old binders .
Her patients hate these binders anyway and most never get close to an acceptable phosphorous level .
Almost everyone in the trials were willing to power thru the first week of diarrhea issues so that they could get off the old binders ....and she thinks her patients will be the same.
XPHOZAH is not a miracle drug . Not everyone has a major response ....but enough do to make it clinically significant .
Once approved I expect most Nephrologists will want to try it
Question now is ...once the NDA is submitted ( fairly soon probably ) will it be a standard 6 mth review or an expedited 2 mth review.
Kiwi
Recent ARDX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:58:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:21:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:19:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:17:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:07:06 PM
- Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2024 12:02:00 PM
- Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults • GlobeNewswire Inc. • 05/21/2024 12:02:21 PM
- Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) • GlobeNewswire Inc. • 05/16/2024 12:01:41 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 05/14/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:03:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:48:10 PM
- Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference • GlobeNewswire Inc. • 05/07/2024 12:01:45 PM
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:02:28 PM
- Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 03/12/2024 08:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:21:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:57:56 PM
- Ardelyx to Participate at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 01:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 11:30:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:01:01 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM